Therapy with immune checkpoint inhibitors has become a new therapeutic option for several types of cancer, but immune-related adverse events can limit their use. 1 Outside of clinical studies, ...
The study of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) has expanded markedly over recent decades, establishing these neuropeptides as pivotal ...
Erythrocyte-αPD-1 conjugates overcome resistance to checkpoint blockade immunotherapy: A first-in-human study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results